Barrons
31 Jul 2026, 12:37 UTC · 7w ago
Verdict
Headline leans bullish. We score REPL +1.00 across two claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
2 claims · scored −1 bearish … +1 bullish
An FDA advisory committee voted that Replimune's skin cancer treatment study is 'clinically meaningful.'
More positive than 98% of claims this week
Replimune's stock price surged following the advisory committee's vote.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The FDA advisory committee's positive vote on its skin cancer treatment led to a surge in stock price.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2d ago
+141.6%
Price agrees with the score
$13.07 vs $5.41 close before publication (Jul 30) · not market-adjusted
REPL chart →
